Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,769 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia.
Baran N, Lodi A, Dhungana Y, Herbrich S, Collins M, Sweeney S, Pandey R, Skwarska A, Patel S, Tremblay M, Kuruvilla VM, Cavazos A, Kaplan M, Warmoes MO, Veiga DT, Furudate K, Rojas-Sutterin S, Haman A, Gareau Y, Marinier A, Ma H, Harutyunyan K, Daher M, Garcia LM, Al-Atrash G, Piya S, Ruvolo V, Yang W, Shanmugavelandy SS, Feng N, Gay J, Du D, Yang JJ, Hoff FW, Kaminski M, Tomczak K, Eric Davis R, Herranz D, Ferrando A, Jabbour EJ, Emilia Di Francesco M, Teachey DT, Horton TM, Kornblau S, Rezvani K, Sauvageau G, Gagea M, Andreeff M, Takahashi K, Marszalek JR, Lorenzi PL, Yu J, Tiziani S, Hoang T, Konopleva M. Baran N, et al. Among authors: kaplan m. Nat Commun. 2022 May 19;13(1):2801. doi: 10.1038/s41467-022-30396-3. Nat Commun. 2022. PMID: 35589701 Free PMC article.
A novel immature natural killer cell subpopulation predicts relapse after cord blood transplantation.
Li L, Chen H, Marin D, Xi Y, Miao Q, Lv J, Banerjee PP, Shaim H, Daher M, Basar R, Imahashi N, Jimenez J, Hu B, Mehta RS, Kerbauy LN, Kaplan M, Mendt M, Ozcan G, Gokdemir E, Hernandez Sanabria M, Li Y, Chen K, Wang J, Muniz-Feliciano L, Zhao WL, Champlin RE, Shpall EJ, Rezvani K. Li L, et al. Among authors: kaplan m. Blood Adv. 2019 Dec 10;3(23):4117-4130. doi: 10.1182/bloodadvances.2019000835. Blood Adv. 2019. PMID: 31821460 Free PMC article.
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.
Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K. Liu E, et al. Among authors: kaplan m. N Engl J Med. 2020 Feb 6;382(6):545-553. doi: 10.1056/NEJMoa1910607. N Engl J Med. 2020. PMID: 32023374 Free PMC article. Clinical Trial.
Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells.
Daher M, Basar R, Gokdemir E, Baran N, Uprety N, Nunez Cortes AK, Mendt M, Kerbauy LN, Banerjee PP, Shanley M, Imahashi N, Li L, Lim FLWI, Fathi M, Rezvan A, Mohanty V, Shen Y, Shaim H, Lu J, Ozcan G, Ensley E, Kaplan M, Nandivada V, Bdiwi M, Acharya S, Xi Y, Wan X, Mak D, Liu E, Jiang XR, Ang S, Muniz-Feliciano L, Li Y, Wang J, Kordasti S, Petrov N, Varadarajan N, Marin D, Brunetti L, Skinner RJ, Lyu S, Silva L, Turk R, Schubert MS, Rettig GR, McNeill MS, Kurgan G, Behlke MA, Li H, Fowlkes NW, Chen K, Konopleva M, Champlin RE, Shpall EJ, Rezvani K. Daher M, et al. Among authors: kaplan m. Blood. 2021 Feb 4;137(5):624-636. doi: 10.1182/blood.2020007748. Blood. 2021. PMID: 32902645 Free PMC article.
GMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored Cord Blood CAR-NK Cells.
Liu E, Ang SOT, Kerbauy L, Basar R, Kaur I, Kaplan M, Li L, Tong Y, Daher M, Ensley EL, Uprety N, Nunez Cortes AK, Yang RZ, Li Y, Shaim H, Reyes Silva F, Lin P, Mohanty V, Acharya S, Shanley M, Muniz-Feliciano L, Banerjee PP, Chen K, Champlin RE, Shpall EJ, Rezvani K. Liu E, et al. Among authors: kaplan m. Front Immunol. 2021 Feb 26;12:626098. doi: 10.3389/fimmu.2021.626098. eCollection 2021. Front Immunol. 2021. PMID: 33717142 Free PMC article.
Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies.
Kerbauy LN, Marin ND, Kaplan M, Banerjee PP, Berrien-Elliott MM, Becker-Hapak M, Basar R, Foster M, Garcia Melo L, Neal CC, McClain E, Daher M, Nunez Cortes AK, Desai S, Inng Lim FW, Mendt MC, Schappe T, Li L, Shaim H, Shanley M, Ensley EL, Uprety N, Wong P, Liu E, Ang SO, Cai R, Nandivada V, Mohanty V, Miao Q, Shen Y, Baran N, Fowlkes NW, Chen K, Muniz-Feliciano L, Champlin RE, Nieto YL, Koch J, Treder M, Fischer W, Okamoto OK, Shpall EJ, Fehniger TA, Rezvani K. Kerbauy LN, et al. Among authors: kaplan m. Clin Cancer Res. 2021 Jul 1;27(13):3744-3756. doi: 10.1158/1078-0432.CCR-21-0164. Epub 2021 May 13. Clin Cancer Res. 2021. PMID: 33986022 Free PMC article.
Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia.
Gaballa MR, Banerjee P, Milton DR, Jiang X, Ganesh C, Khazal S, Nandivada V, Islam S, Kaplan M, Daher M, Basar R, Alousi A, Mehta R, Alatrash G, Khouri I, Oran B, Marin D, Popat U, Olson A, Tewari P, Jain N, Jabbour E, Ravandi F, Kantarjian H, Chen K, Champlin R, Shpall E, Rezvani K, Kebriaei P. Gaballa MR, et al. Among authors: kaplan m. Blood. 2022 Mar 24;139(12):1908-1919. doi: 10.1182/blood.2021013290. Blood. 2022. PMID: 34914826 Free PMC article.
A phase two study of high dose blinatumomab in Richter's syndrome.
Thompson PA, Jiang X, Banerjee P, Basar R, Garg N, Chen K, Kaplan M, Nandivada V, Cortes AKN, Ferrajoli A, Keating MJ, Peterson CB, Andreeff M, Rezvani K, Wierda WG. Thompson PA, et al. Among authors: kaplan m. Leukemia. 2022 Sep;36(9):2228-2232. doi: 10.1038/s41375-022-01649-3. Epub 2022 Aug 8. Leukemia. 2022. PMID: 35941212 Free PMC article. Clinical Trial.
Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering.
Li L, Mohanty V, Dou J, Huang Y, Banerjee PP, Miao Q, Lohr JG, Vijaykumar T, Frede J, Knoechel B, Muniz-Feliciano L, Laskowski TJ, Liang S, Moyes JS, Nandivada V, Basar R, Kaplan M, Daher M, Liu E, Li Y, Acharya S, Lin P, Shanley M, Rafei H, Marin D, Mielke S, Champlin RE, Shpall EJ, Chen K, Rezvani K. Li L, et al. Among authors: kaplan m. Sci Adv. 2023 Jul 28;9(30):eadd6997. doi: 10.1126/sciadv.add6997. Epub 2023 Jul 26. Sci Adv. 2023. PMID: 37494448 Free PMC article.
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial.
Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J, Mohanty V, Dede M, Nieto Y, Uprety N, Acharya S, Liu E, Wilson J, Banerjee P, Macapinlac HA, Ganesh C, Thall PF, Bassett R, Ammari M, Rao S, Cao K, Shanley M, Kaplan M, Hosing C, Kebriaei P, Nastoupil LJ, Flowers CR, Moseley SM, Lin P, Ang S, Popat UR, Qazilbash MH, Champlin RE, Chen K, Shpall EJ, Rezvani K. Marin D, et al. Among authors: kaplan m. Nat Med. 2024 Mar;30(3):772-784. doi: 10.1038/s41591-023-02785-8. Epub 2024 Jan 18. Nat Med. 2024. PMID: 38238616 Free PMC article. Clinical Trial.
3,769 results